Use of intravenous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: Our current understanding

International Immunopharmacology

Volumn 6, Issue 4, 2006, Pages 543-549

  French, Lars E ^a   Trent, Jennifer T ^b   Kerdel, Francisco A ^b  

^a UNIVERSITY OF GENEVA MEDICAL SCHOOL   (Switzerland)

^b UNIVERSITY OF MIAMI   (United States)

Author keywords

Adverse drug reaction; Apoptosis; Fas; Intravenous immunoglobulin

Indexed keywords

CASPASE 10; CASPASE 8; FAS ANTIBODY; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FAS LIGAND; IMMUNOGLOBULIN; IMMUNOGLOBULIN G;

APOPTOSIS; BLISTER; BODY SURFACE; CELL DEATH; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; EPIDERMIS; FEVER; HUMAN; IC 50; KERATINOCYTE; MORTALITY; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; REVIEW; SEPTIC SHOCK; SKIN DISEASE; STATISTICAL SIGNIFICANCE; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME;

EID: 33644504480     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2005.11.012     Document Type: Article

References (17)

1. J.C. Roujeau, and R.S. Stern Severe adverse cutaneous reactions to drugs N Engl J Med 331 1994 1272 1285
2. S. Bastuji-Garin, B. Rzany, R.S. Stern, N.H. Shear, L. Naldi, and J.C. Roujeau Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme Arch Dermatol 129 1993 92 96
3. S. Bastuji-Garin, N. Fouchard, M. Bertocchi, J.C. Roujeau, J. Revuz, and P. Wolkenstein SCORTEN: a severity-of-illness score for toxic epidermal necrolysis J Invest Dermatol 115 2000 149 153
4. J.T. Trent, R.S. Kirsner, P. Romanelli, and F.A. Kerdel Use of SCORTEN to accurately predict mortality in patients with toxic epidermal necrolysis in the United States Arch Dermatol 140 2004 890 892
5. C. Paul, P. Wolkenstein, H. Adle, J. Wechsler, H.J. Garchon, and J. Revuz Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis Br J Dermatol 134 1996 710 714
6. N. Holler, R. Zaru, O. Micheau, M. Thome, A. Attinger, and S. Valitutti Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule Nat Immunol 1 2000 489 495
7. I. Viard, P. Wehrli, R. Bullani, P. Schneider, N. Holler, and D. Salomon Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin Science 282 1998 490 493
8. M. Stella, P. Cassano, D. Bollero, A. Clemente, and G. Giorio Toxic epidermal necrolysis treated with intravenous high-dose immunoglobulins: our experience Dermatology 203 2001 45 49
9. C. Prins, F.A. Kerdel, R.S. Padilla, T. Hunziker, S. Chimenti, and I. Viard Treatment of toxic epidermal necrolysis with high-dose intravenous immunoglobulins: multicenter retrospective analysis of 48 consecutive cases Arch Dermatol 139 2003 26 32
10. J.T. Trent, R.S. Kirsner, P. Romanelli, and F.A. Kerdel Analysis of intravenous immunoglobulin for the treatment of toxic epidermal necrolysis using SCORTEN: The University of Miami experience Arch Dermatol 139 2003 39 43
11. N. Bachot, J. Revuz, and J.C. Roujeau Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression Arch Dermatol 139 2003 33 36
12. E. Campione, G.C. Marulli, A.M. Carrozzo, M.S. Chimenti, A. Costanzo, and L. Bianchi High-dose intravenous immunoglobulin for severe drug reactions: efficacy in toxic epidermal necrolysis Acta Derm Venereol 83 2003 430 432
13. R. Shortt, M. Gomez, N. Mittman, and R. Cartotto Intravenous immunoglobulin does not improve outcome in toxic epidermal necrolysis J Burn Care Rehabil 25 2004 246 255
14. K.M. Brown, G.M. Silver, M. Halerz, P. Walaszek, A. Sandroni, and R.L. Gamelli Toxic epidermal necrolysis: does immunoglobulin make a difference? J Burn Care Rehabil 25 2004 81 88
15. C. Prins, C. Vittorio, R.S. Padilla, T. Hunziker, P. Itin, and J. Forster Effect of high-dose intravenous immunoglobulin therapy in Stevens-Johnson syndrome: a retrospective, multicenter study Dermatology 207 2003 96 99
16. M.V. Morici, W.K. Galen, A.K. Shetty, R.P. Lebouef, T.P. Gouri, and G.S. Cowan Intravenous immunoglobulin therapy for children with Stevens-Johnson syndrome J Rheumatol 27 2000 2494 2497
17. D.W. Metry, P. Jung, and M.L. Levy Use of intravenous immunoglobulin in children with Stevens-Johnson syndrome and toxic epidermal necrolysis: seven cases and review of the literature Pediatrics 112 2003 1430 1436